Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. Company
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Number of employees : 150 people.
Sales per Business
20192020Delta
Innovative Pharmaceutical Products134.38100%127.63100% -5.02%
CHF in Million
Sales per region
2020
Republic of Ireland56.9044.6%
Japan40.1031.4%
United States13.2010.3%
China5.304.2%
Uruguay4.803.8%
Other4.403.4%
Sweden2.902.3%
CHF in Million
Managers
Name Title Age Since
David Veitch Chief Executive Officer 55 2018
Adesh Kaul Chief Financial Officer 46 2019
Laurenz Kellenberger, Dr. Chief Scientific Officer 53 2009
Marc Engelhardt, Dr. Chief Medical Officer 56 2018
Gerrit Hauck, Dr. Chief Technology Officer 56 2018
Steven D. Skolsky Independent Non-Executive Director 64 2010
Ronald Scott Independent Non-Executive Director 65 2018
Domenico Scala, Dr. Chairman 56 2016
Thomas Werner, Dr. Vice Chairman 64 2018
Alf Gunnar Martin Nicklasson, Dr. Independent Non-Executive Director 65 2016
Members of the board
Name Title Age Since
Domenico Scala, Dr. Chairman 56 2016
Steven D. Skolsky Independent Non-Executive Director 64 2010
Ronald Scott Independent Non-Executive Director 65 2018
Thomas Werner, Dr. Vice Chairman 64 2018
Alf Gunnar Martin Nicklasson, Dr. Independent Non-Executive Director 65 2016
Nicole M. Onetto, Dr. Independent Non-Executive Director 67 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 13,014,229 11,521,878 88.5% 1,137,955 8.7% 88.5%
Shareholders
NameEquities%
Basilea Pharmaceutica AG 1,130,737 8.74%
Black Creek Investment Management, Inc. 583,019 4.51%
Norges Bank Investment Management 368,822 2.85%
The Vanguard Group, Inc. 324,904 2.51%
Braginsky Family Office AG 259,500 2.01%
Credit Suisse Asset Management (Schweiz) AG 239,946 1.86%
Zürcher Kantonalbank (Investment Management) 206,458 1.60%
BlackRock Fund Advisors 169,669 1.31%
William Blair Investment Management LLC 134,378 1.04%
UBS Asset Management Switzerland AG 105,073 0.81%
Holdings
NameEquities%Valuation
BASILEA PHARMACEUTICA AG (BSLN) 1,130,737 8.74% 59,002,490 USD
Company contact information
Basilea Pharmaceutica AG
Grenzacherstrasse 487
Basel, Basel-Stadt (Basle Town) 4058

Phone : +41.61.606.11.11
Fax : +41.61.606.11.12
Web : http://www.basilea.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Basilea Pharmaceutica AG
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-13.08%611
MODERNA, INC.321.80%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.43.91%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-12.32%27 670
PHARMARON BEIJING CO., LTD.74.42%24 684
ALNYLAM PHARMACEUTICALS, INC.46.34%22 282
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.74.97%22 164
CUREVAC N.V.-32.02%21 497
HANGZHOU TIGERMED CONSULTING CO., LTD-0.22%21 270
ICON PUBLIC LIMITED COMPANY38.86%20 961
BIO-TECHNE CORPORATION66.73%20 782
NOVAVAX, INC.112.78%17 303
PPD, INC.36.47%16 399
INCYTE CORPORATION-15.57%16 218
QIAGEN N.V.2.46%12 158
BACHEM HOLDING AG88.12%11 321
INTELLIA THERAPEUTICS, INC.182.81%11 055
PRA HEALTH SCIENCES, INC.0.00%10 965
SYNEOS HEALTH, INC.37.59%9 692